# The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

> **NCT02577926** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **RWTH Aachen University** · enrollment: 207 (actual)

## Conditions studied

- Polycythemia Vera (PV)
- Essential Thrombocythemia (ET)

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** BAT

## Key facts

- **NCT ID:** NCT02577926
- **Lead sponsor:** RWTH Aachen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577926, "The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02577926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*